Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Trulieve Cannabis Corp., Trulieve Cannabis Corp. or Organon & Co. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. compare based on key financial metrics to determine which better meets your investment needs.

About Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co.

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Latest Pharmaceuticals and Trulieve Cannabis Corp., Trulieve Cannabis Corp. Stock News

As of July 31, 2026, Trulieve Cannabis Corp. had a $1.7 billion market capitalization, compared to the Pharmaceuticals median of $579.1 million. Trulieve Cannabis Corp.’s stock is NA in 2026, NA in the previous five trading days and up 85.78% in the past year.

Currently, Trulieve Cannabis Corp. does not have a price-earnings ratio. Trulieve Cannabis Corp.’s trailing 12-month revenue is $1.2 billion with a -6.9% net profit margin. Year-over-year quarterly sales growth most recently was -3.7%. There are no analysts providing consensus earnings estimates for the current fiscal year. Trulieve Cannabis Corp. does not currently pay a dividend.

Currently, Trulieve Cannabis Corp. does not have a price-earnings ratio. Trulieve Cannabis Corp.’s trailing 12-month revenue is $1.2 billion with a -6.9% net profit margin. Year-over-year quarterly sales growth most recently was -3.7%. There are no analysts providing consensus earnings estimates for the current fiscal year. Trulieve Cannabis Corp. does not currently pay a dividend.

How We Compare Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. Stock Value Grades

Company	Ticker	Value
Trulieve Cannabis Corp.	TRLV	A
Trulieve Cannabis Corp.	TRLV	A
Organon & Co.	OGN	B

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Trulieve Cannabis Corp. has a Value Score of 81, which is Deep Value. Trulieve Cannabis Corp. has a Value Score of 81, which is Deep Value. Organon & Co. has a Value Score of 73, which is Value.

The Value Stock Winner: It’s a Tie!

Looking at the Value Grade breakdown above, both Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. have a Value Grade of A. For investors who focus solely on a company’s valuation, you will need to conduct further research into both of these companies’ other metrics to see if they could be good additions to your portfolio. It’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co.’s Momentum Grades

Company	Ticker	Momentum
Trulieve Cannabis Corp.	TRLV	A
Trulieve Cannabis Corp.	TRLV	A
Organon & Co.	OGN	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Trulieve Cannabis Corp. has a Momentum Score of 84, which is Very Strong. Trulieve Cannabis Corp. has a Momentum Score of 84, which is Very Strong. Organon & Co. has a Momentum Score of 78, which is Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Trulieve Cannabis Corp.	TRLV	A
Trulieve Cannabis Corp.	TRLV	A
Organon & Co.	OGN	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Trulieve Cannabis Corp. has a Earnings Estimate Score of 95, which is Very Positive. Trulieve Cannabis Corp. has a Earnings Estimate Score of 95, which is Very Positive. Organon & Co. has a Earnings Estimate Score of 32, which is Negative.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. have a grade of A. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether Trulieve Cannabis Corp., Trulieve Cannabis Corp. or Organon & Co. is a better fit.

Other Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. Grades

In addition to Momentum, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Trulieve Cannabis Corp., Trulieve Cannabis Corp. or Organon & Co. Stock?

Overall, Trulieve Cannabis Corp. stock has a Value Score of 81, Momentum Score of 84 and Estimate Revisions Score of 95.

Trulieve Cannabis Corp. stock has a Value Score of 81, Momentum Score of 84 and Estimate Revisions Score of 95.

Organon & Co. stock has a Value Score of 73, Momentum Score of 78 and Estimate Revisions Score of 32.

Comparing Trulieve Cannabis Corp., Trulieve Cannabis Corp. and Organon & Co.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.